A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

NCT05147662 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Treatment of Bleeding
Prophylaxis of Bleeding
Hemophilia A
Children

Interventions

BIOLOGICAL: Damoctocog alfa pegol (Jivi, BAY94-9027)

Sponsor

Bayer